-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13

Benzinga·03/26/2026 15:25:50
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $9 to $13.